A Phase 3 interventional study of Epoetin Hospira in Chronic Renal Failure Requiring Hemodialysis, sponsored by Pfizer. Completed at 110 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-07-19.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing Epoetin Alfa in Kidney Failure, Chronic — none open to participants now, none under way, none of them phase 3. Epoetin Alfa · Kidney Failure, Chronic.
Among the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic, this one is the 5th largest by enrollment, is one of 5 that started in 2012, is one of 5 in phase 3, and was the 11th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →None of the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic is open now. The open studies under Kidney Failure, Chronic, anywhere →
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 5 started in 2012.
This study's enrollment of 406 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 292 across the 13 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 13 have an industry lead sponsor. The 7 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
10 studies in Kidney Failure, Chronic by Pfizer: none open now, none under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 10 studies in Kidney Failure, Chronic by Pfizer, this one is the 3rd largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 6th registered.
Pfizer’s Kidney Failure, Chronic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 10 in Kidney Failure, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the long-term safety in treatment-emergent adverse events (TEAEs) of intravenous (IV) administration of Epoetin Hospira for maintenance of target hemoglobin (Hgb) levels in patients treated for anemia associated with chronic renal failure and on hemodialysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female, patient must be for at least 1 year prior to enrollment, surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or practicing at least 1 of the following methods of :
If hormonal contraceptives are used, the specific contraceptive must have been used for at least 3 months prior to enrollment. If the patient is currently using a hormonal contraceptive, she should also use a barrier method during this study and for at least 30 days following the administration of the patient's last open-label dose.
Exclusion Criteria:
Any of the following that developed during the core study and prior to enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epoetin Hospira will be administered by IV bolus injection 1 to 3 times per week per each patient's dosing schedule. Other ESAs (except for long-acting) may be used as rescue therapy.
Biological: Epoetin Hospira
Intravenous (IV) injection
Also known as: ESA, Erythropoetin Stimulating Agent
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.
Time frame: Up through 7 days after first dose of study drug (Week 1)
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 12
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.
Time frame: Week 1 up to Week 12
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 13 to 24
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.
Time frame: Week 13 up to Week 24
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 25 to 36
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.
Time frame: Week 25 up to Week 36
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 37 to 48
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.
Time frame: Week 37 up to Week 48
Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 48
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.
Time frame: Week 1 up to Week 48
Mean Weekly Dosage of Epoetin Hospira : Over Week 1 to 48
Time frame: Week 1 up to Week 48
Mean Weekly Dosage of Epoetin Hospira for Interval of 12 Weeks
Time frame: Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48
Mean Hemoglobin Levels: Over Week 1 to 48
Time frame: Week 1 up to Week 48
Mean Hemoglobin Levels for Interval of 12 Weeks
Time frame: Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48
Mean Hematocrit Levels: Over Week 1 to 48
Hematocrit is defined as the percentage of red blood cells in the blood.
Time frame: Week 1 up to Week 48
Mean Hematocrit Levels for Interval of 12 Weeks
Hematocrit is defined as the percentage of red blood cells in the blood.
Time frame: Week 1 up to Week 12; Week 13 up to Week 24; Week 25 up to Week 36; Week 37 up to Week 48
Percentage of Participants With Hemoglobin Level Outside the Target Range
Percentage of participants with hemoglobin level outside the target range of 9.0 to 11.0 g/dL were reported.
Time frame: Week 1 up to Week 48
Percentage of Participants Who Received Blood Transfusions
Time frame: Week 1 up to Week 48
Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)
Time frame: Week 1 up to Week 48
Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)
Time frame: Week 1 up to Week 48
Number of Participants With Clinically Significant Change From Baseline in Hemoglobin Levels
Participants with clinically significant change from baseline in hemoglobin levels were upon investigator's discretion.
Time frame: Baseline up to Week 48
Number of Participants Who Received Concomitant Medication
Time frame: Week 1 up to Week 48
Number of Participants With Clinically Significant Change From Baseline in Laboratory Tests
Laboratory tests included: Hematology (hematocrit, hemoglobin, red blood cells count, reticulocytes, white blood cells count, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelets, mean corpuscular volume); Coagulation panel (prothrombin time, international normalized ratio, activated partial thromboplastin time); Chemistry (blood urine nitrogen, creatinine, total bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, calcium, gamma-glutyl transpeptidase, phosphorus, uric acid, total protein, glucose, albumin, C-reactive protein); iron status (plasma ferritin, transferrin saturation). Participants with clinically significant change from baseline in laboratory tests were based on investigator's discretion.
Time frame: Baseline up to Week 48
Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiogram (ECG)
ECG parameters included: PR interval, QRS complex, QT interval and QTC interval. Participants with clinically significant change from baseline in 12-lead ECGs were based on investigator's discretion.
Time frame: Baseline up to Week 48
Number of Participants With Clinically Significant Change From Baseline in Physical Examinations
Physical examination included examination of the skin, eyes, ears, nose, throat, head, neck, thyroid, lungs, chest, abdomen, extremities, lymphatic, cardiovascular, musculoskeletal and neurological systems. Participants for any clinically significant changes in physical examination were based on the investigator's discretion.
Time frame: Baseline up to Week 48
Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies
Percentage of participants with at least 1 positive anti-rhEPO antibody were reported. Radioimmunoprecipitation assay was used to determine the presence of anti-rhEPO antibodies.
Time frame: Baseline, Week 48
Participants with chronic renal failure were receiving Epoetin maintenance therapy in study EPOE-10-01 (NCT01473407) prior to enrollment and treatment in the current study.
| Milestone | Epoetin Hospira |
|---|---|
| Started | 414 |
| Treated | 406 |
| Completed | 295 |
| Not completed | 119 |
| Withdrew: Withdrawal by subject | 17 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Adverse event | 33 |
| Withdrew: Physician decision | 2 |
| Withdrew: Not met inclusion/exclusion criteria | 1 |
| Withdrew: Non-compliant with study procedures | 10 |
| Withdrew: Not treated | 8 |
| Withdrew: Sponsor decision | 11 |
| Withdrew: Missed study drug more than 2 weeks | 7 |
| Withdrew: Relocated | 8 |
| Withdrew: Kidney transplant | 9 |
| Withdrew: Use of standard of care | 9 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.
| Percentage of participants | Epoetin Hospira |
|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1 | 13.0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.
| Percentage of participants | Epoetin Hospira |
|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 12 | 59.4 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.
| Percentage of participants | Epoetin Hospira |
|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 13 to 24 | 57.5 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.
| Percentage of participants | Epoetin Hospira |
|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 25 to 36 | 54.3 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.
| Percentage of participants | Epoetin Hospira |
|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 37 to 48 | 51.7 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment emergent are events that emerged during the treatment period and were absent before treatment or that worsened relative to pretreatment state.
| Percentage of participants | Epoetin Hospira |
|---|---|
| Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 48 | 85.7 |
| Unit per kilogram per week (U/kg/week) | Epoetin Hospira |
|---|---|
| Mean Weekly Dosage of Epoetin Hospira : Over Week 1 to 48 | 95.30 ± 85.515 |
| U/kg/week | Epoetin Hospira |
|---|---|
| Week 1 to Week 12 | 94.93 ± 89.219 |
| Week 13 to Week 24 | 94.84 ± 89.303 |
| Week 25 to Week 36 | 94.01 ± 86.0 |
| Week 37 to Week 48 | 99.55 ± 95.510 |
| g/dL | Epoetin Hospira |
|---|---|
| Mean Hemoglobin Levels: Over Week 1 to 48 | 10.21 ± 0.629 |
| g/dL | Epoetin Hospira |
|---|---|
| Week 1 to Week 12 | 10.26 ± 0.789 |
| Week 13 to Week 24 | 10.25 ± 0.762 |
| Week 25 to Week 36 | 10.18 ± 0.865 |
| Week 37 to Week 48 | 10.21 ± 0.818 |
Hematocrit is defined as the percentage of red blood cells in the blood.
| Percentage of red blood cells | Epoetin Hospira |
|---|---|
| Mean Hematocrit Levels: Over Week 1 to 48 | 32.17 ± 2.164 |
Hematocrit is defined as the percentage of red blood cells in the blood.
| Percentage of red blood cells | Epoetin Hospira |
|---|---|
| Week 1 to Week 12 | 32.26 ± 2.695 |
| Week 13 to Week 24 | 32.21 ± 2.569 |
| Week 25 to Week 36 | 32.03 ± 2.978 |
| Week 37 to Week 48 | 32.17 ± 2.738 |
Percentage of participants with hemoglobin level outside the target range of 9.0 to 11.0 g/dL were reported.
| Percentage of participants | Epoetin Hospira |
|---|---|
| Percentage of Participants With Hemoglobin Level Outside the Target Range | 90.1 |
| Percentage of participants | Epoetin Hospira |
|---|---|
| Percentage of Participants Who Received Blood Transfusions | 9.7 |
| Percentage of participants | Epoetin Hospira |
|---|---|
| Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL) | 13.9 |
| Percentage of participants | Epoetin Hospira |
|---|---|
| Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL) | 20.9 |
Participants with clinically significant change from baseline in hemoglobin levels were upon investigator's discretion.
| Participants | Epoetin Hospira |
|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Hemoglobin Levels | 0 |
| Participants | Epoetin Hospira |
|---|---|
| Number of Participants Who Received Concomitant Medication | 406 |
Laboratory tests included: Hematology (hematocrit, hemoglobin, red blood cells count, reticulocytes, white blood cells count, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelets, mean corpuscular volume); Coagulation panel (prothrombin time, international normalized ratio, activated partial thromboplastin time); Chemistry (blood urine nitrogen, creatinine, total bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, sodium, potassium, magnesium, calcium, gamma-glutyl transpeptidase, phosphorus, uric acid, total protein, glucose, albumin, C-reactive protein); iron status (plasma ferritin, transferrin saturation). Participants with clinically significant change from baseline in laboratory tests were based on investigator's discretion.
| Participants | Epoetin Hospira |
|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Laboratory Tests | 0 |
ECG parameters included: PR interval, QRS complex, QT interval and QTC interval. Participants with clinically significant change from baseline in 12-lead ECGs were based on investigator's discretion.
| Participants | Epoetin Hospira |
|---|---|
| Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiogram (ECG) | 2 |
Physical examination included examination of the skin, eyes, ears, nose, throat, head, neck, thyroid, lungs, chest, abdomen, extremities, lymphatic, cardiovascular, musculoskeletal and neurological systems. Participants for any clinically significant changes in physical examination were based on the investigator's discretion.
| Participants | Epoetin Hospira |
|---|---|
| Number of Participants With Clinically Significant Change From Baseline in Physical Examinations | 0 |
Percentage of participants with at least 1 positive anti-rhEPO antibody were reported. Radioimmunoprecipitation assay was used to determine the presence of anti-rhEPO antibodies.
| Percentage of participants | Epoetin Hospira |
|---|---|
| Baseline | 0 |
| Week 48 | 0.6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epoetin Hospira | — | 168/406 (41.4%) | 277/406 (68.2%) |
| Event | Epoetin Hospira |
|---|---|
| SepsisInfections and infestations | 18/406 |
| PneumoniaInfections and infestations | 16/406 |
| Acute myocardial infarctionCardiac disorders | 13/406 |
| HyperkalaemiaMetabolism and nutrition disorders | 13/406 |
| Cardiac failure congestiveCardiac disorders | 10/406 |
| Angina pectorisCardiac disorders | 7/406 |
| Cardio-respiratory arrestCardiac disorders | 7/406 |
| Cardiac arrestCardiac disorders | 6/406 |
| HypoglycaemiaMetabolism and nutrition disorders | 6/406 |
| HypertensionVascular disorders | 6/406 |
| Event | Epoetin Hospira |
|---|---|
| Muscle spasmsMusculoskeletal and connective tissue disorders | 81/406 |
| NauseaGastrointestinal disorders | 58/406 |
| HeadacheNervous system disorders | 51/406 |
| DiarrhoeaGastrointestinal disorders | 49/406 |
| DizzinessNervous system disorders | 47/406 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 42/406 |
| HypotensionVascular disorders | 41/406 |
| VomitingGastrointestinal disorders | 39/406 |
| CoughRespiratory, thoracic and mediastinal disorders | 36/406 |
| Arteriovenous fistula site complicationInjury, poisoning and procedural complications | 35/406 |
Safety analysis set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Epoetin Hospira |
|---|---|
| Mean | 57.45 ± 12.062 |
| Sex: Female, Male(Participants) | Epoetin Hospira |
|---|---|
| Female | 169 |
| Male | 237 |
Showing the first 100 of 110 sites across 2 countries. Choose a country and city above to see the rest.
Ran from Jul 2012 to primary completion in Jan 2015, 29 months.
Results were first posted in Jul 2018, 3 years 6 months after primary completion. A results delay was requested in Dec 2015.
Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's 29 months is close to that.
Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa